Tissue Engineering Market Size To Reach $43.13 Billion By 2030

Tissue Engineering Market Growth & Trends

The global tissue engineering market size is estimated to reach USD 43.13 billion by 2030, growing at an estimated CAGR of 14.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing incidence of chronic diseases, such as cardiovascular diseases, diabetes, and orthopedic disorders, has driven the demand for tissue engineering solutions that can repair or replace damaged tissues. Advances in biomaterials, 3D bioprinting, stem cell research, and gene editing techniques have propelled the field of tissue engineering, enabling the development of complex and functional tissues.

The allogeneic tissue transplant method effectively addresses the challenges and limitations associated with the use and accessibility of autologous transplants. In addition, the advancement of specialized procedures, such as implant fixing and sterilization, aimed at converting allogeneic implants into biostatic implants, is anticipated to boost revenue generation in this market.

Tissue regeneration technology is gaining popularity due to its effective products and low rejection rates, leading to an increase in regeneration treatments. Pre-clinical research is currently focused on the use of tissue-engineered vascular grafts in cardiovascular surgery and treatment. Moreover, tissue-engineered bladders can now be successfully implanted outside of the patient's body. Despite these advancements, the market's growth is hindered by challenges such as the high cost of product development and ethical concerns surrounding stem cell research and tissue-engineered products.

 Request a free sample copy or view report summary: Tissue Engineering Market Report

Tissue Engineering Market Report Highlights

• The orthopedics, musculoskeletal, & spine segment held the largest revenue of 59.21% market share in 2024, owing to the increasing prevalence of musculoskeletal disorders.

• North America dominated the market and accounted for the largest revenue share of 51.30% in 2024, owing to rising awareness of stem cell therapy, the growing geriatric population, and the rising incidence of chronic diseases.

• The market for tissue engineering in Asia Pacific is estimated to witness the fastest CAGR of 19.04% during the forecast period.

Tissue Engineering Market Segmentation

Grand View Research has segmented the global tissue engineering market on the basis of application and region:

Tissue Engineering Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cord blood & Cell Banking

• Cancer

• GI, Gynecology

• Dental

• Skin & Integumentary

• Urology

• Orthopedics, Musculoskeletal, & Spine

• Neurology

• Cardiology & Vascular

• Others

Tissue Engineering Regional Outlook (Revenue in USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players of Tissue Engineering Market

• Zimmer Biomet Holdings, Inc.

• AbbVie (Allergan)

• Becton Dickinson and Company

• B. Braun

• Integra LifeSciences Corporation

• Organogenesis Holdings Inc.

• Medtronic

• ACell, Inc.

• Athersys, Inc.

• Tissue Regenix Group plc

• Stryker Corporation

• RTI Surgical, Inc.

• ReproCell, Inc.

• Baxter International, Inc.